Conference Presentation, Panel, Fireside Chat
Wednesday Lunch: Walking the Drug-Pricing Tightrope
- The health system is expected to endure even if drug pricing legislation fails to pass within the current year, though the administration predicts healthcare spending will consume one in every five dollars by 2026.
- Significant systemic strain is anticipated due to approximately 50 additional high-cost drugs in the pipeline, each priced between $500,000 and $2 million, which could threaten the long-term sustainability of the healthcare system.
- While there is hope for bipartisan legislation to address pricing issues with action expected by year-end or shortly thereafter, the administration remains prepared to implement its own proposals if such legislation does not pass.
- Part D premiums have decreased by 11 percent to reach their lowest levels in seven years, yet current Part B payment structures based on average sales price plus a percentage add-on continue to incentivize higher drug prices and prescriptions.
- Future payment models are projected to shift toward value-based arrangements and integrated care, with the possibility of "21st Century Cures 2.0" incorporating innovative systems that align payments with the patient life cycle of treatments like gene therapies.
- Specific incentives for antimicrobial development are proposed, including higher payments for the first couple of years following FDA approval to counteract potential policy-induced barriers to innovation.
- Potential revenue cuts or fixed government price settings could reduce Research and Development budgets by 10 to 15 new drugs over a decade, potentially impacting patient access to next-generation therapies and cures.
- Manufacturers may increase launch prices under value-based pricing models to account for future discounts, and current policies could inadvertently stifle biosimilar competition, resulting in billions of dollars in lost savings.
- Concerns persist that government policy set without appropriate incentives could thwart innovation, although the extent of the impact on development varies among economists, with some arguing that accessibility is a critical component of true innovation.